Analyzing the potential effect of FGFR3 driver mutations on survival of lung cancer patients, we observed a trend toward better survival for FGFR3 mutations in lung adenocarcinoma, compared with lung adenocarcinoma patients with wild-type FGFR3 and those harboring KRAS mutation, similar to as reported in the bladder and skin cancer [33]. This evidence concerns the gene KRAS and lung adenocarcinoma.